Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:46:23 2026-01-12 pm EST			5-day change	1st Jan Change
109.14 ^USD	-1.25%		+1.44%	+3.54%

07:01am	Moderna expects $1.9 billion in sales, trims costs forecast for 2025	RE
Jan. 09	Sector Update: Health Care Stocks Decline Late Afternoon	MT

HSBC Adjusts Price Target on Merck & Co. to $120 From $100, Maintains Buy Rating

Published on 12/10/2025 at 06:10 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

07:01am	Moderna expects $1.9 billion in sales, trims costs forecast for 2025	RE
Jan. 09	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 09	Sector Update: Health Care Stocks Mixed Friday Afternoon	MT
Jan. 09	Sector Update: Health Care	MT
Jan. 09	Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals	MT
Jan. 09	Morgan Stanley Adjusts Price Target on Merck to $101 From $102, Maintains Equalweight Rating	MT
Jan. 09	Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell	MT
Jan. 09	Morgan Stanley Trims Price Target on Merck to $101 From $102, Keeps Equalweight Rating	MT
Jan. 09	Merck reportedly consiering a major acquisition (Revolution Medicines)
Jan. 09	Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal	CI
Jan. 08	AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty	RE
Jan. 08	Merck & Co. in Talks to Acquire Revolution Medicines	MT
Jan. 08	Price tag of $28bn to $32bn was being discussed as part of Merck-Revolution Medicines deal - FT	RE
Jan. 08	Merck in talks to buy biotech Revolution in up to $32 billion deal, FT reports	RE
Jan. 08	Merck in talks to buy biotech Revolution Medicines, Financial Times reports	RE
Jan. 08	Merck in talks to buy cancer drugmaker Revolution Medicines-FT	RE
Jan. 08	Merck Shares Rise After Wolfe Research Upgrade	MT
Jan. 08	Rothschild & Co Redburn Adjusts Merck Price Target to $135 From $125, Maintains Buy Rating	MT
Jan. 08	Independent expert group to review HPV vaccine evidence after US recommendation change	RE
Jan. 08	Wolfe Research Upgrades Merck & Co. to Outperform From Peer Perform, Price Target is $135	MT
Jan. 07	UBS Adjusts Price Target on Merck & Co to $130 From $105, Maintains Buy Rating	MT
Jan. 07	Vaxxas appoints former Merck global vaccines president David Peacock as CEO	RE
Jan. 07	Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC	CI
Jan. 07	Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer	MT
Jan. 07	Merck Successfully Completes Cash Tender Offer for Cidara Therapeutics	MT

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Jan. 12 - J.P. Morgan Healthcare Conference

More about the company